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Poster Session I S321achievement of steady state. The half life (t1/2) of voriconazole was
5.0965.15 hours. The dose normalized (per mg) AUC (mg*hr/ml)
was 0.11160.081. Voriconazole dose did not correlate with
AUCo-N (r2 5 0.028). There was a good correlation between
AUCo-N and Ctrough (r
2 5 0.94). Population estimates of bioavail-
ability, clearance, apparent volume of the central compartment (Vc)
and apparent volume of peripheral compartment (Vp) were 46.5%,
5.76L/hr, 19.4L and 58.8L.
Conclusions: The bioavailability of voriconazole was significantly
lower in pediatric BMT patients than in non-transplant adult sub-
jects. The t1/2 at steady state tended to be lower than adult patients.
Our study suggests that pediatric patients may require dosing higher
than 7mg/kg twice daily. The wide individual variability and the lack
of correlation between dose and AUC support therapeutic monitor-
ing of voriconazole and dose adjustments based on steady state blood
levels.
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SAFETY AND EFFICACY OF INTRAVENOUS PENTAMIDINE IN CHILDREN
AND ADOLESCENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
DeMasi, J.1, Cox, J.2, Koh, A.1,3, Aquino, V.M.1,3 1Children’s Medical
Center Dallas, Dallas, TX; 2The Huntsville Hospital for Women and
Children, Huntsville, AL; 3University of Texas Southwestern Medical
Center at Dallas, Dallas, TX
Background: Pneumocystis carnii pneumonia (PCP) is a potentially
life-threatening but preventable infection thatmay occur after hema-
topoietic stem cell transplantation (HSCT). Although prophylaxis
with trimethoprim-sulfamethoxazole has been shown to be effective
in the prevention of PCP, the development of neutropenia limits its
use in the early post-transplant period. Aerosolized pentamidine is
a commonly used second line agent, but the need to have the drug
administered via respiratory route may increase the risk of infection.
Intravenous pentamidine has been used in the prevention of PCP in
the post-transplant period, although there are few trials published in
the literature evaluating its safety and efficacy. A recent series study-
ing the use of intravenous pentamidine as secondary prophylaxis in
children with cancer receiving conventional chemotherapy reported
a breakthrough rate of 1.3%.We evaluated the overall efficacy of in-
travenous pentamidine, toxicity profile, and overall impact in the
prevention of PCP in HSCT recipients.
Patients and Methods: Retrospective review of medical records of
children who underwent HSCT from Jan 1, 2005 – October 1, 2011
who received intravenous pentamidine as first line PCP prophylaxis
initiated at admission. Demographic, clinical, microbiologic, man-
agement, and outcome data was collected.
Results: 170 consecutive pediatric patients were given intravenous
pentamidine before myeloablation and then every 28 days until the
subject was 6 months post-HSCT, had stable neutrophil recovery
(ANC.1000 without growth factor support), had discontinued im-
munosuppression and did not have evidence of chronic graft versus
host disease.). No cases of PCP were seen in this cohort. Ten (6%)
had a grade I side effect of nausea/vomiting requiring slower infusion
time and 2 (1%) had a grade IV reaction with anaphylaxis and hypo-
tension requiring transfer to the intensive care unit for management.
Conclusions: Our pediatric HSCT patients receiving pentamidine
had no episodes of breakthrough PCP, and the incidence of side ef-
fects was low. Given the potential neutropenic effects of trimetho-
prim-sulfamethoxazole, compliance with drug administration, and
inferior efficacy of other PCP prophylactic medications, intravenous
pentamidine should be considered as first line therapy in the preven-
tion of PCP in children undergoing HSCT.312
IDENTIFYING RELIGIOUS/SPIRITUAL (R/S) PERSPECTIVES OF ADOLES-
CENTS AND YOUNG ADULTS RECEIVING BLOOD AND MARROW TRANS-
PLANT: A QUALITATIVE STUDY
Hegner, M.A., Ragsdale, J.R., Grossoehme, D.H., Mueller, M.,
Davies, S.M. Cincinnati Children’s Hospital Medical Center, Cincinnati,
OHBone marrow transplant (BMT) or hematopoietic stem-cell trans-
plantation (HSCT) are difficult treatments for life threatening ill-
nesses; the emotional stress experienced by patients of any age is
high. Religion/spirituality (R/S) is commonly used by Americans, in-
cluding adolescents, to cope. Religion can be described as a personal
or communal system of religious attitudes, practices and beliefs.
Spirituality is generally described as the feelings, experiences, and
practices that arise from the search for the sacred or God. We hy-
pothesize that the experience of illness and BMT would affect
what adolescents and young adults (A/YA) believe about R/S and
their way of using faith to make meaning and to cope. The specific
aim was to understand from the patients’ perspective how they use
R/S and how their R/S changes in the course of their BMT experi-
ence. Our goal is to develop a conceptual model of how R/S con-
structs operate in the experiences of A/YA undergoing BMT and
also begin to develop an empirically-based pastoral care interven-
tion. This is a qualitative study of R/S in persons aged 13-29 years
undergoing HSCT or BMT. Semi-structured interviews are com-
pleted in the first 100 days post-transplant and at 1- year post-trans-
plant. Interviews are audiotaped, transcribed, and coded for common
themes using grounded theory methodology. Seven interviews (50%
of those eligible) have been completed. Preliminary analysis shows
that prayer is themost commonly used R/S practice, and that thema-
jority of participants believe that their illnesses are ‘‘part of God’s
plan’’. Without the development of evidence for clinical practice,
chaplains may offer care which may or may not be effective. We
will propose a conceptual model suitable for future testing, and ulti-
mately contribute to a better psycho- social- and spiritual- outcomes
for A/YA undergoing BMT or HSCT.313
DRUG INTERACTION BETWEEN ORAL VORICONAZOLE AND ORAL
CALCINEURIN INHIBITOR AND ITS RELATIONSHIP WITH BLOOD CON-
CENTRATION OF VORICONAZOLE IN RECIPIENTS OF ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Sadahira, K., Mori, T., Kato, J., Yamane, A., Okamoto, S. Keio Univer-
sity School of Medicine, Tokyo, Japan
Background: Drug interaction between calcineurin inhibitors (cy-
closporine A (CsA) and tacrolimus) and voriconazole is well known.
However, it has yet to be fully evaluated in the setting of hematopoi-
etic stem cell transplantation (HSCT). We have previously shown
a wide variability in the drug interaction between voriconazole and
calcineurin inhibitors in HSCT recipients, which led to a conclusion
that uniform reduction of the dose of calcineurin inhibitors was not
recommended on initiating voriconazole. However, in that study,
the route of administration of both drugs was not taken into consid-
eration. In the present study, the magnitude of drug interaction
between oral voriconazole and oral CsA was examined in HSCT
recipients, and its relation with the blood concentration of voricona-
zole was also evaluated.
Patients and Methods: Nineteen recipients of allogeneic HSCT
who had already been on a steady dose of oral CsA, and were started
on oral voriconazole (200 mg per body every 12 h) for the treatment
or prophylaxis of fungal infection could be evaluated. The concen-
tration/dose (C/D; (ng/ml)/(mg/kg)) ratio of CsA was calculated
7–10 days after initiating voriconazole when the increased blood
levels of calcineurin inhibitors had stabilized. The plasma level
of voriconazole was measure by high-performance liquid chroma-
tography.
Results: The median C/D ratio of CsA significantly increased to
113.7 (ng/ml)/(mg/kg) (range, 62.4-189.5) after initiating voricona-
zole administration as compared with that before (63.1 (range, 41.1-
189.0): P\0.001). Median increased rate of C/D ratios were 83.0%
with a range of 0.3% to 224.7%. The plasma level of voriconazole
on the day of evaluating C/D ratio was 1.9860.84 mg/ml. The in-
creased rate of C/D ratio of tacrolimus did not correlate with the
plasma level of voriconazole (r 5 -0.17, P 5 0.50).
Conclusion: The magnitude of the drug interaction between oral
CsA and oral voriconazole demonstrates a wide variability, whose in-
creased rate of C/D ratio ranged between 0.3% and over 200%. This
wide variability could not be explained by the bioavailability of vor-
iconazole. The mechanisms of this variability should be explored in
a future study.
